Fiduciary Planning’s Biogen BIIB Stock Holding History

Fiduciary Planning’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-84	Closed	-$23K	–	82
2021 Q1	$23K	Sell	84 -1	-1%	-$270	0.03%	103
2020 Q4	$21K	Hold	85	–	–	0.03%	107
2020 Q3	$24K	Buy	+85	New	+$23.7K	0.04%	84

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fiduciary Planning's BIIB Position: Q2 2021 in Review

Fiduciary Planning sold out of Biogen (BIIB) in Q2 2021, closing a stake of 84 shares — an estimated $23K sold.

Fiduciary Planning first reported a position in BIIB in Q3 2020 and held it in 3 quarters. The position peaked at $24K in Q3 2020. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Fiduciary Planning reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Fiduciary Planning sold 84 Biogen shares in Q2 2021, an estimated $23K.
Fiduciary Planning first reported a position in Biogen in Q3 2020 and held it in 3 quarters.
Fiduciary Planning's Biogen position peaked at $24K in Q3 2020.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Fiduciary Planning's 13F filing for Q2 2021, filed 6 Aug 2021.